MARKET

KTTAW

KTTAW

Pasithea Therapeutics Corp
NASDAQ
0.0205
-0.0032
-13.50%
Opening 11:58 12/18 EST
OPEN
0.0229
PREV CLOSE
0.0237
HIGH
0.0229
LOW
0.0205
VOLUME
8.24K
TURNOVER
--
52 WEEK HIGH
0.1198
52 WEEK LOW
0.0108
MARKET CAP
--
P/E (TTM)
-0.0039
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTAW last week (1208-1212)?
Weekly Report · 3d ago
PASITHEA THERAPEUTICS CORP. <KTTA.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING
Reuters · 12/08 11:11
Weekly Report: what happened at KTTAW last week (1201-1205)?
Weekly Report · 12/08 09:28
PASITHEA THERAPEUTICS ANNOUNCES CLOSING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK
Reuters · 12/02 12:00
Pasithea Therapeutics Director Lawrence Steinman Reports Acquisition of Common Shares
Reuters · 12/01 14:07
Pasithea Therapeutics CEO Tiago Marques Reports Acquisition of Common Shares
Reuters · 12/01 13:57
Pasithea Therapeutics Director Simon Dumesnil Acquires Common Shares
Reuters · 12/01 13:54
Weekly Report: what happened at KTTAW last week (1124-1128)?
Weekly Report · 12/01 09:26
More
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTAW stock methods without spending real money on the virtual paper trading platform.